ALPHAMAB ONCOLOGY

Communiqués Alphamab Oncology

Actions

9966

KYG0330A1013

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:05 31/05/2024			Varia. 5j.	Varia. 1 janv.
2,54 ^HKD	+4,53 %		-45,61 %	-61,75 %

29/05	Les actions de Hong Kong clôturent en baisse après une séance mitigée à Wall Street	MT
29/05	L'essai clinique de phase 3 d'Alphamab pour le traitement du cancer du pancréas n'atteint pas le critère statistique prédéfini ; les actions chutent de 38%.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China	29/11/21	AQ
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - ABSTRACTS AND E-POSTERS OF RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT 2021 ASCO ANNUAL MEETING	07/05/21	PU
Alphamab Oncology : (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING	27/04/21	PU
Alphamab Oncology : FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 11, 2021	27/04/21	PU
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING	12/04/21	PU
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER	30/03/21	PU
Alphamab Oncology : Reports Full Year 2020 Financial Results and Business Highlights	23/03/21	PR
Alphamab Oncology : ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME	23/03/21	PU
Alphamab Oncology : Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.	09/03/21	PR
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S.	08/03/21	PU
TRACON Pharmaceuticals : Announces Acceptance of the Envafolimab NDA by the NMPA in China for Priority Review	20/01/21	AQ
TRACON Pharmaceuticals : Announces Acceptance of the Envafolimab NDA by the NMPA in China that was submitted by its Corporate Partners Alphamab Oncology and 3D Medicines	31/12/20	AQ
TRACON Pharmaceuticals : Announces Submission for Approval of Envafolimab with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines	17/11/20	AQ
TRACON Pharmaceuticals : Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer	22/09/20	AQ
Alphamab Oncology : Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody	10/06/20	PR
Alphamab Oncology : and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer	09/06/20	PR
Alphamab Oncology : Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States	16/04/20	PR
Alphamab Oncology :, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China	30/03/20	PR
Alphamab Oncology : Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)	27/03/20	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT